<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ATOVAQUONE</span><br/>(a-to'va-quone)<br/><span class="topboxtradename">Mepron, </span><span class="topboxtradename">Mepron Suspension<br/></span><b>Classifications:</b> <span class="classification"> antiinfective</span>; <span class="classification">antiprotozoal</span><br/><b>Prototype: </b>Metronidazole<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>750 mg/5 mL suspension</p>
<h1><a name="action">Actions</a></h1>
<p>Atovaquone is an antiprotozoal with antipneumocystic activity, including <i>Pneumocystis carinii</i> and the <i>Plasmodium</i> species. Mechanism of action against <i>P. carinii</i> is unknown. In the <i>Plasmodium</i> species, the site of action is linked to inhibition of the electron transport system in the mitochondria. This results in
         the inhibition of nucleic acid and ATP synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against <i>P. carinii</i> and the <i>Plasmodium</i> species.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Second-line oral therapy of mild to moderate <i>P. carinii</i> pneumonia (PCP) in immunocompromised patients intolerant of cotrimoxazole.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>May be effective in the treatment of cerebral toxoplasmosis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of potential life-threatening allergies to atovaquone.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Severe PCP, concurrent pulmonary diseases, older adults, pregnancy (category C), or lactation. Safe use in children is not
         established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Mild to Moderate <i>Pneumocystis carinii</i> Pneumonia (PCP)</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 750 mg (5 mL) suspension b.i.d. for 21 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with meals, because food significantly enhances absorption.</li>
<li>Store at room temperature 15°30° C (59°86° F) unless otherwise directed by the manufacturer.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Fever.</span>
<span class="typehead">CV:</span> Hypotension. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache, insomnia, dizziness, strange or vivid dreams, anxiety, depression</span>. <span class="typehead">Hematologic:</span> Anemia, neutropenia. <span class="typehead">Metabolic:</span> Hyponatremia, hypoglycemia. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, diarrhea, vomiting,</span> abdominal pain, anorexia, dyspepsia, oral candidiasis, oral ulcers. <span class="typehead">Skin:</span>
<span class="speceff-common">Rash,</span> pruritus, erythema multiforme. <span class="typehead">Respiratory:</span> Cough, sinusitis. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May cause increase in <b>amylase</b> and other <b>liver function tests.</b>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Zidovudine</b> may increase risk of bone marrow toxicity. <span class="typehead">Food:</span> Oral absorption is increased 3- to 4-fold when administered with food, especially with fatty foods. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Poorly absorbed from GI tract. Absorption is improved when taken with a fatty meal. <span class="typehead">Duration:</span> 623 wk after a 3-wk course of therapy. <span class="typehead">Distribution:</span> Penetrates poorly into cerebrospinal fluid; &gt;99.9% protein bound. <span class="typehead">Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> &gt;94% excreted in feces over 21 d (enterohepatically cycled). <span class="typehead">Half-Life:</span> 23 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess for therapeutic failure in patients with GI disorders that may limit absorption of drug.</li>
<li>Lab tests: Monitor CBC with differential, blood glucose, serum sodium, creatinine, BUN, and serum amylase periodically. Report
            abnormal elevations in these values; drug may need to be discontinued.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>
            							Note: It is necessary to take this drug exactly as prescribed because it is slowly eliminated from the body.
            						
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>